These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 36867282)

  • 81. Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement.
    Guiu S; Michiels S; André F; Cortes J; Denkert C; Di Leo A; Hennessy BT; Sorlie T; Sotiriou C; Turner N; Van de Vijver M; Viale G; Loi S; Reis-Filho JS
    Ann Oncol; 2012 Dec; 23(12):2997-3006. PubMed ID: 23166150
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Estrogen receptor (ER), progesterone receptor (PR), and HER2 expression pre- and post- neoadjuvant chemotherapy in primary breast carcinoma: a single institutional experience.
    Kinsella MD; Nassar A; Siddiqui MT; Cohen C
    Int J Clin Exp Pathol; 2012; 5(6):530-6. PubMed ID: 22949935
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Chemosensitivity predicted by BluePrint 80-gene functional subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST).
    Whitworth P; Stork-Sloots L; de Snoo FA; Richards P; Rotkis M; Beatty J; Mislowsky A; Pellicane JV; Nguyen B; Lee L; Nash C; Gittleman M; Akbari S; Beitsch PD
    Ann Surg Oncol; 2014 Oct; 21(10):3261-7. PubMed ID: 25099655
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Association between mammographic density and basal-like and luminal A breast cancer subtypes.
    Razzaghi H; Troester MA; Gierach GL; Olshan AF; Yankaskas BC; Millikan RC
    Breast Cancer Res; 2013; 15(5):R76. PubMed ID: 24008056
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Re-testing of predictive biomarkers on surgical breast cancer specimens is clinically relevant.
    Robertson S; Rönnlund C; de Boniface J; Hartman J
    Breast Cancer Res Treat; 2019 Apr; 174(3):795-805. PubMed ID: 30659433
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Impact of molecular subtypes classification concordance between preoperative core needle biopsy and surgical specimen on early breast cancer management: Single-institution experience and review of published literature.
    Meattini I; Bicchierai G; Saieva C; De Benedetto D; Desideri I; Becherini C; Abdulcadir D; Vanzi E; Boeri C; Gabbrielli S; Lucci F; Sanchez L; Casella D; Bernini M; Orzalesi L; Vezzosi V; Greto D; Mangoni M; Bianchi S; Livi L; Nori J
    Eur J Surg Oncol; 2017 Apr; 43(4):642-648. PubMed ID: 27889196
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.
    Cheang MC; Chia SK; Voduc D; Gao D; Leung S; Snider J; Watson M; Davies S; Bernard PS; Parker JS; Perou CM; Ellis MJ; Nielsen TO
    J Natl Cancer Inst; 2009 May; 101(10):736-50. PubMed ID: 19436038
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Agreement between molecular subtyping and surrogate subtype classification: a contemporary population-based study of ER-positive/HER2-negative primary breast cancer.
    Lundgren C; Bendahl PO; Borg Å; Ehinger A; Hegardt C; Larsson C; Loman N; Malmberg M; Olofsson H; Saal LH; Sjöblom T; Lindman H; Klintman M; Häkkinen J; Vallon-Christersson J; Fernö M; Rydén L; Ekholm M
    Breast Cancer Res Treat; 2019 Nov; 178(2):459-467. PubMed ID: 31432367
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Expression of ERBB gene family in females with breast cancer and its correlation with clinicopathological characteristics of the disease.
    Soosanabadi M; Ghahfarokhi AM; Pourghazi F; Ehtesham N; Mirfakhraie R; Atanesyan L; Keyhani E; Behjati F
    Mol Biol Rep; 2022 Sep; 49(9):8547-8553. PubMed ID: 35763181
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel.
    Fountzilas G; Dafni U; Bobos M; Batistatou A; Kotoula V; Trihia H; Malamou-Mitsi V; Miliaras S; Chrisafi S; Papadopoulos S; Sotiropoulou M; Filippidis T; Gogas H; Koletsa T; Bafaloukos D; Televantou D; Kalogeras KT; Pectasides D; Skarlos DV; Koutras A; Dimopoulos MA
    PLoS One; 2012; 7(6):e37946. PubMed ID: 22679488
    [TBL] [Abstract][Full Text] [Related]  

  • 91. The regrouping of Luminal B (HER2 negative), a better discriminator of outcome and recurrence score.
    Yang ZJ; Liu YX; Huang Y; Chen ZJ; Zhang HZ; Yu Y; Wang X; Cao XC
    Cancer Med; 2023 Feb; 12(3):2493-2504. PubMed ID: 35909232
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Molecular phenotypes of DCIS predict overall and invasive recurrence.
    Williams KE; Barnes NLP; Cramer A; Johnson R; Cheema K; Morris J; Howe M; Bundred NJ
    Ann Oncol; 2015 May; 26(5):1019-1025. PubMed ID: 25678586
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Metastatic breast carcinoma in pleural fluid: Correlation of receptor and HER2 status with the primary carcinoma-a pilot study.
    Francis IM; Alath P; George SS; Jaragh M; Al Jassar A; Kapila K
    Diagn Cytopathol; 2016 Dec; 44(12):980-986. PubMed ID: 27666130
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Distribution of molecular breast cancer subtypes among Algerian women and correlation with clinical and tumor characteristics: a population-based study.
    Cherbal F; Gaceb H; Mehemmai C; Saiah I; Bakour R; Rouis AO; Boualga K; Benbrahim W; Mahfouf H
    Breast Dis; 2015; 35(2):95-102. PubMed ID: 25736840
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Luminal A versus luminal B breast cancer: MammaTyper mRNA versus immunohistochemical subtyping with an emphasis on standardised Ki67 labelling-based or mitotic activity index-based proliferation assessment.
    Finsterbusch K; Decker T; van Diest PJ; Focke CM
    Histopathology; 2020 Apr; 76(5):650-660. PubMed ID: 31846096
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Differential survival and recurrence patterns of patients operated for breast cancer according to the new immunohistochemical classification: analytical survey from 1997 to 2012.
    García Fernández A; Chabrera C; García Font M; Fraile M; Gónzalez S; Barco I; González C; Cirera L; Veloso E; Lain JM; Pessarrodona A; Giménez N
    Tumour Biol; 2013 Aug; 34(4):2349-55. PubMed ID: 23605321
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Differential distribution of microRNAs in breast cancer grouped by clinicopathological subtypes.
    Li JY; Jia S; Zhang WH; Zhang Y; Kang Y; Li PS
    Asian Pac J Cancer Prev; 2013; 14(5):3197-203. PubMed ID: 23803104
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Comparisons of p53, KI67 and BRCA1 expressions in patients with different molecular subtypes of breast cancer and their relationships with pathology and prognosis.
    Li Y; Zhang X; Qiu J; Pang T; Huang L; Zeng Q
    J BUON; 2019; 24(6):2361-2368. PubMed ID: 31983107
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Technical validation of an RT-qPCR in vitro diagnostic test system for the determination of breast cancer molecular subtypes by quantification of ERBB2, ESR1, PGR and MKI67 mRNA levels from formalin-fixed paraffin-embedded breast tumor specimens.
    Laible M; Schlombs K; Kaiser K; Veltrup E; Herlein S; Lakis S; Stöhr R; Eidt S; Hartmann A; Wirtz RM; Sahin U
    BMC Cancer; 2016 Jul; 16():398. PubMed ID: 27389414
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Intertumoral heterogeneity of bifocal breast cancer: a morphological and molecular study.
    Finsterbusch K; van Diest PJ; Focke CM
    Breast Cancer Res Treat; 2024 Jun; 205(2):413-421. PubMed ID: 38453779
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.